KardiaAI vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

KardiaAI

by AliveCor

ElucidVivo A.3

by Elucid

AI Verdict

KardiaAI specializes in AI-powered analysis of ECG rhythms for detecting cardiac conditions like AFib, bradycardia, and tachycardia. In contrast, ElucidVivo A.3 provides quantitative AI analysis of arterial plaque composition from CT angiography to aid in atherosclerosis patient stratification. While both are FDA-cleared AI solutions in cardiology, they address distinct diagnostic areas within cardiovascular health.

Choose KardiaAI if…

Choose KardiaAI if your primary need is real-time or continuous AI-powered analysis of ambulatory ECG rhythms for the detection of various cardiac arrhythmias such as atrial fibrillation, bradycardia, or tachycardia. This tool is ideal for integrating medical-grade heart rhythm analysis into mobile health applications or existing ECG devices to provide immediate insights into a patient's electrical heart activity.

View KardiaAI →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you require advanced, quantitative AI-powered analysis of arterial plaque composition and stability from CT angiography images. This system is best suited for cardiologists, radiologists, and vascular surgeons who need to stratify atherosclerosis patients, visualize plaque characteristics in 3D, and optimize treatment decisions based on detailed structural insights into arterial disease.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	KardiaAI	ElucidVivo A.3
Pricing	Subscription-based for advanced features and services.	Unknown
Deployment	Mobile app, cloud-based.	Cloud and on-premise secure deployment.
FDA Status	1 AI-estimated	1 AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

KardiaAI

KardiaAI is designed for broad accessibility, integrating into mobile apps and web platforms for both healthcare professionals and individuals. Its user experience emphasizes simplicity and speed for recording and analyzing ECGs. ElucidVivo A.3, while integrating with PACS/EMR, is a specialized medical imaging system that likely requires more specific training within clinical workflows.

Clinical Value

ElucidVivo A.3

Both tools offer significant, FDA-cleared clinical value. However, ElucidVivo A.3 provides a deeper, more prognostic insight into complex cardiovascular disease through its histology-validated quantitative analysis of arterial plaque composition and stability, including the derivation of FFRct. This offers highly personalized risk assessment and treatment optimization for atherosclerosis.

Pricing & Value

KardiaAI

KardiaAI offers transparent, subscription-based pricing that is publicly available and accessible for individual users and smaller practices. ElucidVivo A.3's pricing is not publicly disclosed, requiring direct contact, which makes a direct comparison on value difficult for general users, although it has secured favorable reimbursement pathways for institutions.

Enterprise Readiness

ElucidVivo A.3

ElucidVivo A.3 demonstrates stronger enterprise readiness with its explicit integration capabilities with PACS/EMR, DICOM support, and stated 'SOC 2 / HIPAA-aligned data protection'. These features are crucial for seamless integration into complex hospital IT environments and specialized medical imaging workflows.

Innovation

ElucidVivo A.3

ElucidVivo A.3 presents a more cutting-edge application of AI by providing histology-validated quantitative analysis of arterial plaque composition and stability, including Lipid-Rich Necrotic Core, and deriving FFRct from non-invasive CT angiography. This offers novel and highly specialized insights into plaque vulnerability.

Support & Docs

KardiaAI

KardiaAI provides publicly accessible user manuals in multiple languages, troubleshooting guides, and clear contact information for technical support, along with API documentation for developers. While ElucidVivo A.3, as an enterprise solution, would have support, its documentation and support details are not as explicitly or publicly detailed.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	KardiaAI	ElucidVivo A.3
Tool Name	KardiaAI	ElucidVivo A.3
Company	AliveCor	Elucid Bioimaging
Core Functionality	FDA-cleared AI software library for analyzing ambulatory ECG rhythms, detecting various cardiac conditions.	FDA-cleared AI-powered medical image analysis system for quantitative analysis of arterial plaque composition and stability from CT angiography.
Primary AI Focus	ECG rhythm analysis	Arterial plaque composition analysis from CT images
Key Detections/Analyses	Detection of atrial fibrillation, bradycardia, tachycardia, normal sinus rhythm, Sinus Rhythm with Premature Ventricular Contractions (PVCs), Sinus Rhythm with Wide QRS, Sinus Rhythm with Supraventricular Ectopy (SVE); ECG noise filtering.	Quantitative analysis of Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications; 3D visualization of highlighted vessels; Derivation of fractional flow reserve (FFRct).
Specialties Supported	Cardiology, Emergency Medicine, Internal Medicine	Cardiology, Radiology, Vascular Surgery

Videos

Demos, reviews, and walkthroughs featuring KardiaAI and ElucidVivo A.3.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into a physician's existing clinical workflow and what is the depth of EHR integration for each?

KardiaAI is an API library designed for integration into mobile apps and web platforms for ECG analysis, and it offers direct EHR integration to automatically pull ECGs into systems like Epic. ElucidVivo A.3 is a software application that integrates with PACS/EMR systems, allowing for the processing, review, and analysis of CT angiography images within typical clinical workflow patterns.

For which specific cardiovascular conditions and patient populations is each tool primarily designed, and which medical specialties would benefit most?

KardiaAI is primarily designed for the detection of various cardiac arrhythmias, including atrial fibrillation, bradycardia, and tachycardia from ambulatory ECGs, benefiting cardiologists, emergency physicians, and internal medicine specialists. ElucidVivo A.3 focuses on quantitative analysis of arterial plaque composition and stability from CT angiography to stratify atherosclerosis patients and optimize treatment decisions, serving cardiologists, radiologists, and vascular surgeons.

What level of clinical accuracy and validation can be expected from each tool's analytical capabilities?

KardiaAI provides 'medical-grade accuracy for heart rhythm data' in its ECG analysis, with studies showing high sensitivity and specificity for detecting conditions like AFib. ElucidVivo A.3's quantitative plaque analysis, including lipid-rich necrotic core and calcifications, is validated against ground-truth histology, which is considered the gold standard for plaque characterization.

What is the typical learning curve for physicians and clinical staff to effectively utilize each tool, and what is the expected time-to-value?

KardiaAI, as an API integrated into existing platforms, aims for a minimal end-user learning curve, with value realized quickly once integrated into familiar workflows. ElucidVivo A.3, as a dedicated software application, involves a learning curve for navigating its interface and interpreting detailed plaque analysis, with time-to-value dependent on integration and training within the imaging workflow.

What are the key considerations for deploying each tool across multiple clinical sites, and what kind of ongoing support is provided?

For KardiaAI, multi-site rollout would leverage its API and SDK for integration into various mobile/web platforms and EHR systems, with AliveCor offering support for its technology. ElucidVivo A.3, as a software application, would require standard IT planning for installation and integration with PACS/EMR across multiple sites, with support details typically provided directly by Elucid Bioimaging.

Are customer references or case studies available to demonstrate the real-world impact and physician satisfaction with these tools?

The provided information for KardiaAI mentions that AliveCor has a history of building deep customer loyalty and has published studies demonstrating clinical utility and workflow advantages. For ElucidVivo A.3, the information highlights published studies and ongoing clinical trials, and the company has announced new clinical and commercial leadership, suggesting a focus on real-world impact.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring KardiaAI or ElucidVivo A.3

Backers

Who funded each tool's parent company.